FDA clears SeaStar Medical trial enrollment
SeaStar Medical says the NEUTRALIZE-AKI pivotal trial is evaluating its SCD therapy in 339 adults with acute kidney injury in the ICU receiving continuous renal replacement therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.